Presentation is loading. Please wait.

Presentation is loading. Please wait.

Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization–intracytoplasmic.

Published byRegina McGee Modified over 6 years ago

Similar presentations

Presentation on theme: "Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization–intracytoplasmic."— Presentation transcript:

1 Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization–intracytoplasmic sperm injection cycles with a gonadotropin-releasing hormone antagonist? A retrospective single-center study  Nikolaos P. Polyzos, M.D., Ph.D., Scott M. Nelson, M.D., Ph.D., Dominic Stoop, M.D., Ph.D., Milie Nwoye, M.D., Peter Humaidan, M.D., Ph.D., Ellen Anckaert, M.D., Ph.D., Paul Devroey, M.D., Ph.D., Herman Tournaye, M.D., Ph.D.  Fertility and Sterility  Volume 100, Issue 2, Pages (August 2013) DOI: /j.fertnstert Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

2 Figure 1 Receiver operator characteristic (ROC) curves for antimüllerian hormone (AMH) for the prediction of low and excessive ovarian responders. Fertility and Sterility  , DOI: ( /j.fertnstert ) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Download ppt "Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization–intracytoplasmic."

Similar presentations

Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States  David B. Seifer, M.D., Valerie.

Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States  David B. Seifer, M.D., Valerie.
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Clinical outcome of non–hCG-primed oocyte in vitro maturation treatment in patients with polycystic ovaries and polycystic ovary syndrome  Michel De Vos,

Clinical outcome of non–hCG-primed oocyte in vitro maturation treatment in patients with polycystic ovaries and polycystic ovary syndrome  Michel De Vos,
Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.

Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.
Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M

Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M
Longitudinal changes in maternal serum concentrations of antimüllerian hormone in individual women during conception cycles and early pregnancy  Kristina.

Longitudinal changes in maternal serum concentrations of antimüllerian hormone in individual women during conception cycles and early pregnancy  Kristina.
Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study  Thi.

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study  Thi.
Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection.

Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection.
Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation.

Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation.
Samuel Santos-Ribeiro, M. D. , Johannie Siffain, M. D. , Nikolaos P

Samuel Santos-Ribeiro, M. D. , Johannie Siffain, M. D. , Nikolaos P
Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.
1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.

1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.
Effects and clinical significance of GnRH antagonist administration for IUI timing in FSH superovulated cycles: a meta-analysis  Ioannis P. Kosmas, M.D.,

Effects and clinical significance of GnRH antagonist administration for IUI timing in FSH superovulated cycles: a meta-analysis  Ioannis P. Kosmas, M.D.,
Janet Kwee, M. D. , Roel Schats, M. D. , Ph. D. , Joseph McDonnell, M

Janet Kwee, M. D. , Roel Schats, M. D. , Ph. D. , Joseph McDonnell, M
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
Anti-Müllerian hormone for the assessment of ovarian response in GnRH-antagonist- treated oocyte donors  Nikolaos P. Polyzos, Dominic Stoop, Christophe.

Anti-Müllerian hormone for the assessment of ovarian response in GnRH-antagonist- treated oocyte donors  Nikolaos P. Polyzos, Dominic Stoop, Christophe.
Impact of circulating levels of total and bioavailable serum vitamin D on pregnancy rate in egg donation recipients  Alberta Fabris, M.D., Alberto Pacheco,

Impact of circulating levels of total and bioavailable serum vitamin D on pregnancy rate in egg donation recipients  Alberta Fabris, M.D., Alberto Pacheco,
Zhi-Yong Yang, M.D., Ri-Cheng Chian, Ph.D.  Fertility and Sterility 

Zhi-Yong Yang, M.D., Ri-Cheng Chian, Ph.D.  Fertility and Sterility 
The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.

The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.
An initial low response predicts poor outcome in in vitro fertilization/intracytoplasmic sperm injection despite improved ovarian response in consecutive.

An initial low response predicts poor outcome in in vitro fertilization/intracytoplasmic sperm injection despite improved ovarian response in consecutive.

Similar presentations

Ads by Google